Adjunctive Phenobarbital for Alcohol Withdrawal Syndrome: A Focused Literature Review

Area of Science:

• Pharmacology
• Critical Care Medicine
• Emergency Medicine

Background:

• Severe alcohol withdrawal syndrome (AWS) presents a significant clinical challenge.
• Current treatment often relies on benzodiazepines, but refractory cases require alternative strategies.
• Phenobarbital is explored as an adjunctive therapy for severe AWS.

Purpose of the Study:

• To systematically review the literature on the use of phenobarbital as an adjunctive treatment for severe alcohol withdrawal syndrome (AWS).
• To evaluate the efficacy and safety of phenobarbital in different clinical settings for AWS management.

Main Methods:

• A literature search was conducted in PubMed and EMBASE for studies on phenobarbital in severe AWS.
• Included studies were randomized controlled trials (RCTs) and cohort studies published in English.
• Seven studies from emergency departments, general medicine wards, and intensive care units were identified.

Main Results:

• Phenobarbital demonstrated benzodiazepine-sparing effects in emergency and general medicine settings.
• In ICUs, protocols guiding phenobarbital use may reduce the need for mechanical ventilation.
• Adjunctive phenobarbital was generally well-tolerated across studies.

Conclusions:

• The precise role of phenobarbital in severe AWS remains unclear due to the heterogeneity of study designs and outcomes.
• While showing promise in reducing benzodiazepine use and mechanical ventilation, limitations hinder definitive recommendations.
• Further high-quality research is warranted to establish clear guidelines for adjunctive phenobarbital in severe AWS.